Cohort Analysis of 67 Charcot-Marie-Tooth Italian Patients: Identification of New Mutations and Broadening of Phenotype Expression Produced by Rare Variants

Rosangela Ferese¹, Rosa Campopiano¹, Simona Scala¹, Carmelo D’Alessio¹, Marianna Storto¹, Fabio Buttari¹, Diego Centonze¹,², Giancarlo Logroscino³,⁴, Chiara Zecca⁵, Stefania Zampatti¹,³,⁵, Francesco Formi¹,⁴, Vittoria Cianci⁷, Elisabetta Manfroi⁸, Emiliano Giardina⁵,⁸, Mauro Magnani⁹, Antonio Suppa¹,¹¹, Giuseppe Novelli¹,⁹ and Stefano Gambardella¹,¹⁰

¹IRCCS Neuromed, Pozzilli, Italy, 2Laboratory of Synaptic Immunopathology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, 3Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, The University of Bari “Aldo Moro,” 4Pia Fondazione Card G. Panico” Hospital Tricase, Lecce, Italy, 5Department of Basic Medicine Neuroscience and Sense Organs, University “Aldo Moro” Bari, Bari, Italy, 6Genomic Medicine Laboratory, IRCCS Fondazione Santa Lucia, Rome, Italy, 7Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 8Regional Epilepsy Centre, Great Metropolitan Hospital Bianchi-Melacrino-Morelli, Reggio Calabria, Italy, 9Department of Neuroscience Neurogenetics, Santa Maria Hospital, Terni, Italy, 10Department of Biomedicine and Prevention, University of Rome “Tor Vergata,” Rome, Italy, 11Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy

Charcot-Marie-Tooth (CMT) disease is the most prevalent inherited motor sensory neuropathy, which clusters a clinically and genetically heterogeneous group of disorders with more than 90 genes associated with different phenotypes. The goal of this study is to identify the genetic features in the recruited cohort of patients, highlighting the role of rare variants in the genotype-phenotype correlation. We enrolled 67 patients and applied a diagnostic protocol including multiple ligation-dependent probe amplification for copy number variation (CNV) detection of PMP22 locus, and next-generation sequencing (NGS) for sequencing of 47 genes known to be associated with CMT and routinely screened in medical genetics. This approach allowed the identification of 26 patients carrying a whole gene CNV of PMP22. In the remaining 41 patients, NGS identified the causative variants in eight patients in the genes HSPB1, MFN2, KIF1A, GDAP1, MTMR2, SH3TC2, KIF5A, and MPZ (five new vs. three previously reported variants; three sporadic vs. five familial variants). Familial segregation analysis allowed to correctly interpret two variants, initially reported as “variants of uncertain significance” but re-classified as pathological. In this cohort is reported a patient carrying a novel familial mutation in the tail domain of KIF5A [a protein domain previously associated with familial amyotrophic lateral sclerosis (ALS)], and a CMT patient carrying a HSPB1 mutation, previously reported in ALS. These data indicate that combined tools for gene association in medical genetics allow dissecting...
INTRODUCTION

Charcot-Marie-Tooth (CMT) disease, also known as hereditary motor and sensory neuropathy, is a common, clinically heterogeneous group of inherited peripheral neuropathies with an estimated prevalence of one in 2,500 individuals (Wiszniewski et al., 2013; Di Vincenzo et al., 2014).

CMT is clinically, neurophysiologically, and genetically heterogeneous. It is most commonly characterized by sensory loss that starts in the lower limbs and progresses slowly in a length-dependent manner. This produces progressive distal muscle atrophy, weakness, distal sensory loss, foot deformities, and depressed tendon reflexes (Shy et al., 2005; Rossor et al., 2013).

The clinical classification is based on age at onset, distribution of muscle weakness, sensory loss, walking difficulties, and foot deformities (Rossor et al., 2013). Neuropathology allows subdividing the disease into a demyelinating (CMT1) and axonal (CMT2) forms depending on whether the median motor nerve conduction velocity (NCV) is below or above 38 m/s, respectively. A third form, intermediate CMT, has both demyelinating and axonal features and NCV between 25 and 45 m/s (Reilly and Shy, 2009; Berciano et al., 2012).

The duplication of PMP22 is the most common cause of CMT, with a prevalence up to 40% in some populations (Reilly and Shy, 2009; Abe et al., 2011; Saporta et al., 2011; Murphy et al., 2012; Østern et al., 2013; Sivera et al., 2013). Then, approximately 100 different genes have been linked to CMT-like phenotypes which are associated with related conditions involved in axonal transport, myelin structure, and membrane metabolism that have been found in multiple unrelated families or confirmed by functional studies (Saifi et al., 2003; Saporta et al., 2011; Azzedine et al., 2012; Vallat et al., 2013; IPNMD, 2014; OMIM, 2014; Washington University, 2014).

Therefore, the large spectrum of genetically identifiable disease alleles complicates the molecular diagnosis. Genetic heterogeneity is associated with a wide spectrum of phenotypes, complicated by the fact that mutations in the same gene cause different phenotypes (Reilly and Shy, 2009; Azzedine et al., 2012; OMIM, 2014). Furthermore, sporadic cases of CMT are not uncommon due to autosomal recessive inheritance, reduced penetrance, late-onset, small family size, and de novo mutations (Braathen et al., 2011; Saporta et al., 2011; Vallat et al., 2013).

In this study, we enrolled 67 patients and applied a diagnostic protocol including multiple ligation-dependent probe amplification (MLPA) for copy number variation (CNV) detection of PMP22 locus, and next-generation sequencing (NGS) for sequencing of 47 genes known to be associated with CMT and routinely screened in medical genetics.

The goal of this study is to identify the genetic features in the recruited cohort of patients, highlighting the role of rare variants in the genotype-phenotype correlation.

MATERIALS AND METHODS

Study Population

We collected blood or DNA samples from 67 unrelated patients with a clinical diagnosis of CMT from January 2013 to December 2019 at IRCCS Neuromed Institute (Italy). Genomic DNA was isolated from peripheral blood leukocytes according to standard procedures (QIAamp DNA Blood Mini Kit – QIAGEN).

Clinical Data

Diagnosis of CMT includes the presence of slowly progressive neuropathy with or without family history and after exclusion of other common causes of acquired neuropathy. CMT subtype was classified as CMT if both motor and sensory nerves were similarly affected, and dHMN or HSN if the neuropathy showed exclusive or predominant involvement of motor or sensory nerves, respectively. CMT patients were further subdivided into demyelinating CMT if conduction velocity of the nondominant median or ulnar nerve was ≤38 m/s and axonal or intermediate CMT if >38 m/s.

Literature Review

A systematic review of the literature was conducted to identify the detection rate of genetic variants and the clinical phenotype of CMT patients. Pubmed, Medline, and Embase database identified 23 cohort analysis studies consisting of Italian and European CMT patients in the period between 1997 and 2020 (Supplementary Table S1).

Multiple Ligation-Dependent Probe Amplification

The commercially available kit P405 (MRC-Holland, Amsterdam, Netherlands) was used for the multiplex dosage. This SALSA MLPA Probemix contains 42 MLPA probes with amplification products between 130 and 445 nt: 15 probes located in the 17p12 region (PMP22 gene), two flanking probes, seven probes in the MPZ gene, five probes in the GJB1 gene, 10 reference probes detecting autosomal chromosomes, and three probes on the X-chromosome. The MLPA was performed on DNA from patients, and four normal subjects were used as internal controls.
Next-Generation Sequencing Panel
The NGS analysis was performed using the Seq Cap EZ Choice Enrichment Kits (Hoffmann-La Roche, Basel) on an Illumina MiSeq (San Diego, CA). A full list of genes sequenced is provided in Table 1. All coding exons of the RefSeq transcripts of the genes and 15 base pairs of the flanking introns were targeted, except for GJB1, for which the target region is extended 860 bases upstream of the ATG start codon to include the nerve-specific promoter region. 99% of the coding exons were sequenced with a minimal read depth of 30X.

GenomeUp software1 was used for data analysis. It provides automated annotation (Best Practices workflows of GATK v4.1 for germline variant calling), alignment of sequence reads to the reference genome GRCh37/hg19, and selection of potentially pathogenic variants. Direct evaluation of data sequence was performed by the Integrative Genomics Viewer v.2.3. Mutation re-sequencing and segregation analysis were performed by the Sanger sequencing ABI 3130xl Genetic Analyzer (Applied Biosystems).

Data Analysis and Variant Interpretation
Variants were classified as pathogenic (class 5), likely pathogenic (class 4), and variants of uncertain significance (VoUS; class 3) according to American College of Medical Genetics Guideline for germline variant classification (Li et al., 2017). To this aim, public databases were used (VarSome https://varsome.com; GnomAD https://gnomad.broadinstitute.org). In silico analyses of variants were performed using SIFT,2 PolyPhen2,3 PROVEAN,4 and Mutation Assessor.5 The new mutations identified have been submitted in ClinVar database.6

RESULTS
Multiple Ligation-Dependent Probe Amplification Analysis
The variation of the whole PMP22 gene CNV was assessed through MLPA, confirming the clinical diagnosis in 26 out of 67 patients (38.8%). In detail, 20/67 (30%) were carriers of the heterozygote whole gene duplication, thus confirming the clinical diagnosis of CMT1A; 5/67 (7.4%) were carriers of the heterozygote whole gene deletion, confirming HNPP clinical diagnosis; and one was a carrier of a rare whole gene mosaic duplication of 1.5-Mb in heterozygous in PMP22 gene (MIM 601097), considered as pathogenic (Rautenstrauss et al., 1998) and thus responsible for CMT disease 1A, autosomal dominant (MIM 118220). (Family ID 564, II:1; Figure 1A), classified as sporadic on anamnesis.

Causative Variants Identified as Sporadic
Family ID 882
The proband, a 45 years old female (II:1; Figure 1B), onset at 7 years old, presented with a moderate hypostenia, axonal neuropathy, and normal conduction velocity (>45 m/s). She is a carrier of the new heterozygous stop mutation: NM_001127660.1:c.[2258dupT], NP_001121132.1:p.(Gln754AlafsTer9; rs773371488) in mitofusin-2 (MFN2; MIM 608507) considered as pathogenic and thus responsible for CMT disease 2A2A and autosomal dominant (MIM 609260). The variant was considered as sporadic since it is not present in the mother (I:2), and her father (I:1) is reported as neurological healthy.

Family ID 896
The proband, a 45 years old male (II:1; Figure 1C), onset at 20 years old, presented with axonal and demyelinating neuropathy with a very slow conduction velocity (>15 m/s). Molecular analysis identified the known heterozygous stop mutation: NM_000530.8: c.[306delA], NP_000521: p.(Asp104ThrfsTer14), (rs281865125) in MPZ (MIM 159440) considered as pathogenic (Warner et al., 1996) and thus responsible for CMT disease-dominant intermediate D (MIM 607791). The variant was considered sporadic. Family members were not available for testing, but both his mother I:2 and father I:1 were reported as neurological healthy before the age of 20 years old.

Family ID 402
The proband, a 76 years old female (II:1; Figure 1D), onset at 56, presented with progressive ankle instability and gait...
difficulties with and foot drop. She had a diagnosis of axonal neuropathy with an intermediate conduction velocity (38 m/s). Molecular analysis identified the known heterozygous missense mutation: NM_001540.3:c.[570G > T], NP_061845.2:p.(Cys155Arg) in GADP1 (MIM 606598) considered as pathogenic and thus responsible for CMT disease axonal, autosomal dominant, and type 2K (MIM 607831). His sister (II:9) has a similar condition but was not available for testing.

Family ID 1196

The proband, 69 years old male (II:1; Figure 1F), onset at 57 years old, presented with axonal neuropathy. He showed a normal conduction velocity. Molecular analysis identified a new heterozygous stop mutation: NM_018972.2: c.[140delA], NP_061845.2: p.(Lys47ArgfsTer3) in GADP1 (MIM 606598) considered as pathogenic and thus responsible for CMT disease axonal, autosomal dominant, and type 2K (MIM 607831). His sister (II:9) has a similar condition but was not available for testing.

Family ID 125

The proband, a 45 years old male (II:1; Figure 1G), onset at 20 years old, presented with early onset demyelinating neuropathy with slow conduction velocity (18 m/s). Molecular analysis identified the known homozygous splicing mutations: NM_024577.3: c.[805 + 2T > C], (rs139052887T > C) in SH3TC2 (MIM 608206) considered as pathogenic (Piccosquito et al., 2016) and thus responsible for CMT disease axonal, autosomal recessive, and type 4C (MIM 601596). Both parents (I:1 and I:2) are heterozygote healthy carriers of this variant.

Family ID 1141

The proband a 60 years old male (II:1; Figure 1H), onset at 40 years old, presented with neuropathy and spastic paraplegia. He showed an intermediate conduction velocity (40 m/s). Molecular analysis identified a new heterozygous deletion mutation: NM_004984.2:c.[2868_2870delTCT], NP_004975.2:p.(Leu957del), (rs765668490: C > T) in KIF5A (MIM 602821) considered as likely pathogenic and thus responsible for spastic paraplegia 10 with neuropathy and autosomal dominant (MIM 604187). This variant is familiar since it is present in his affected sister (II:2) and absent in his healthy sister (II:4).

Family ID 580

The proband a 30 years old female (II:1; Figure 1I), onset at 22, presented with axonal neuropathy and an intermediate conduction velocity (<35 m/s). Molecular analysis identified the new homozygous missense mutation: NM_016156.5:c.[463T > C], NP_057240.3:p.(Arg1778Trp), (rs765668490: C > T) in KIF1A (MIM 601255), initially considered as VoUS, but classified as likely pathogenic because of its presence in his affected brother (II:2). This variant is responsible for neuropathy, hereditary sensory, type IIC, and autosomal recessive (MIM 614213).

**Causative Variants Identified as Familiar**

**Family ID 184**

The proband, a 67 years old male (II:1; Figure 1E), onset at 45 years old, presented with neuropathy, mild hypostenia of the distal musculature, and hearing loss. He showed a slow conduction velocity (25 m/s) and signs of pyramidal tract dysfunction. Molecular analysis identified a new heterozygous missense mutation: NM_001244008.2:c.[5332C > T], NP_001230937:p.(Arg1778Trp), (rs765668490: C > T) in KIF1A (MIM 601255), initially considered as VoUS, but classified as likely pathogenic because of its presence in his affected brother (II:2). This variant is responsible for neuropathy, hereditary sensory, type IIC, and autosomal recessive (MIM 614213).

**TABLE 1 | Target genes included in NGS Panel.**

| Gene | Ref sequence | MIM |
|------|--------------|-----|
| AARS | NM_001605.2 | 601065 |
| ALT1 | NM_005309 | 138200 |
| ARHGEF10 | NM_001308152 | 608236 |
| ATP7A | NM_0000526.2 | 300011 |
| BSC1L2 | NM_001122955.3 | 606158 |
| C5T | NM_012073.5 | 610150 |
| DMN2 | NM_001005680.2 | 602378 |
| DYNCH1 | NM_001376.4 | 600112 |
| ERG2 | NM_0003599.3 | 129010 |
| FGF4 | NM_013291.2 | 611197 |
| FIUREG4 | NM_014845.5 | 608590 |
| GARS | NM_020472.2 | 600287 |
| GDA1P | NM_018972.2 | 606598 |
| GJB1 | NM_000166.5 | 304040 |
| HSPB1 | NM_001540.2 | 602195 |
| HSPB8 | NM_014365.2 | 608014 |
| IFRD1 | NM_003640.5 | 603502 |
| IKBKAP | NM_001197081.1 | 603722 |
| KIF1A | NM_001244008.2 | 601255 |
| KIF1B | NM_015074.3 | 605995 |
| KIF5A | NM_004862.3 | 603795 |
| LMNA | NM_170707.2 | 150330 |
| LRASAM1 | NM_138361.5 | 610933 |
| MED25 | NM_000973.2 | 610197 |
| MIF2 | NM_014874.3 | 608507 |
| MIPZ | NM_000530.6 | 159440 |
| MTMR2 | NM_016156.5 | 603557 |
| NDRG1 | NM_001135242.1 | 605282 |
| NEFL | NM_006156 | 162280 |
| NPHS1 | NM_000052.6 | 300011 |
| PRK | NM_001244008.2 | 605995 |
| RAD7A | NM_004637.3 | 602298 |
| REEPI | NM_004637 | 602298 |
| SBF2 | NM_002962.3 | 601997 |
| SEPT9 | NM_00113491 | 604061 |
| SH3TC2 | NM_004862.3 | 604878 |
| SLC12A6 | NM_001540.2 | 602195 |
| SMAD1 | NM_005900.3 | 601595 |
| SOD1 | NM_000045 | 147450 |
| ST10 | NM_000549 | 604457 |
| TDP1 | NM_001008744.2 | 607198 |
| SURF1 | NM_003312.4 | 185620 |
| TGFBI | NM_000660 | 190180 |
| TRPV4 | NM_021625.4 | 605427 |
| TTR | NM_0208556 | 176300 |

For each gene is reported: (i) name (GeneCards: The Human Gene Database), (ii) Ref sequence (NCBI Reference Sequence Database), and (iii) MIM (Gene/Locus MIM number).
Ferese et al. Analysis of 67 Charcot-Marie-Tooth Italian Patients

Frontiers in Genetics | www.frontiersin.org 5 July 2021 | Volume 12 | Article 682050

FIGURE 1 | Pedigree and electropherograms of class 4 and 5 mutations identified by next-generation sequencing (NGS). (A) Family ID: 564, MPLA analysis and identified a mosaic duplication of 1.5-Mb (17p11.2–12); (B) Family ID: 882, heterozygous stop mutation in mitofusin-2 (MFN2) gene: NM_001127660.1:c.[2258dupT], NP_001121112.1:p.Gln754AlafsTer8; rs773371488; (C) Family ID: 896, heterozygous stop mutation in MPZ gene: NM_000530.8:c.[306delA], NP_000521: p.(Asp104ThrfsTer14), rs281865125; (D) Family ID: 402, heterozygous missense mutation in HSPB1 gene: NM_001540.3:c.517G > C], NP_000531.1:p.Gln190His; (E) Family ID: 184, heterozygous missense mutation in KIF1A gene: NM_001244008.2:c.[532C > T], NP_001244008.2:p.(Arg1778Trp), rs768884490; (F) Family ID: 1196, heterozygous stop mutation in QADP1 gene: NM_012972.2:c.[140delA], NP_061845.2:p.(Lys47ArgfsTer10); (G) Family ID: 1251, homozygous splicing mutations in SH3TC2 gene: NM_024577.3:c.[805 + 2T > C], rs139632889; (H) Family ID: 1141, heterozygous deletion mutation in KIF5A gene: NM_004984.2:c.[2868_2870delTCT], NP_004975.2:p.(Leu957del); and (I) Family ID: 580, homozygous missense mutation in MTMR2 gene: NM_016156.5:c.[463T > C], NP_057240.3:p.(Cys155Arg).
FIGURE 2 | Genotype and phenotype of Charcot-Marie-Tooth (CMT) patients from this study (A), and CMT patients reviewed from the literature (B). (A) Variants identified in 67 CMT patients (blue: copy number variation 38.8%; orange: MPZ mutation 1.5%; gray: HSPB1 mutation 1.5%; light yellow: MFN2 mutation 1.5%; light blue: KIF1A mutation 1.5%; green: GAPD1 mutation 1.5%; dark blue: MTMR2 mutation 1.5%; brown: KIF5A mutation 1.5%; dark gray: SH3TC2 mutation 1.5%; yellow: no cause detected 41.8%; and dark green: uncertain pathogenetic 7.4%). (B) This graphic compares detection yield in CMT phenotypes obtained from the literature. (light yellow: CMT1; orange: CMT2; gray: CMT4; light blue: CMTX; green: HMSN; and blue: undiagnosed). Bar 1: data obtained in this study; Bar 2: data obtained from three Italian studies; and Bar 3: data obtained from 20 European studies (see Supplementary Material).
## TABLE 2 | Genetic and clinical data in the cohort of patients analyzed. Clinical (A) and genetic (B) features of the 15 CMT patients (16 variants) identified by NGS.

| Fam ID | Gene/SNP | HGVSc | HGVSp | dbsNP ID | Genotype | Phenotype | ACMG | Clin Var | ACMG | AO | Family history | CMT subtype | CV | CV subtype | Reference |
|--------|----------|-------|-------|----------|----------|-----------|-------|----------|-------|----|---------------|-------------|----|-------------|-----------|
| 882    | MNF2     | NM_001127660.1 | c.[225delT] | rs733071480 | Heterozygous | 609260 | 5 | SCVO011424047 | PM1-PM2-PP3 | 45 | 7 | NO | 2 | >4.5 | Normal | Our study |
| 896    | MPZ      | NM_000530.8 | c.[306delA] | rs281865125 | Heterozygous | 607791 | 5 | SCVO00129882 | PM1-PM2-PM2 | 45 | 20 | NO | 1 | >2 | Very slow | Warner et al., 1996 |
| 1196   | GDAP1    | NM_018972.2 | c.[140delA] | rs607831 | Heterozygous | 607831 | 5 | SCVO01142419 | PM1-PM2-PM2 | 69 | 57 | YES | 2 | >4.5 | Normal | Our study |
| 1251   | SH3TC2   | NM_024577.3 | c.[805 + 2T > G] | rs100352887 | Heterozygous | 601596 | 5 | SCVO01142420 | PM1-PM2-PP3 | 45 | 20 | YES | 1 | 18 | Slow | Pescosolito et al., 2016 |
| 564    | PMP22    | NM_153321 | g.dup(17p12 | | 606995 | 4 | SCVO01142420 | PM1-PM2-PP3 | 80 | 56 | NO | 2 | 38 | Intermediate | Our study |
| 402    | HSPB1    | NM_001540.3 | c.[570G > C] | rs675223790 | Heterozygous | 606995 | 4 | SCVO01142420 | PM1-PM2-PP3 | 80 | 56 | NO | 2 | 38 | Intermediate | Our study |
| 1141   | KIF5A    | NM_0004954.2 | c.[2868_2870delTCT] | rs57651426 | Heterozygous | 604187 | 4 | SCVO01142425 | PM1-PM2-PM4-PP3 | 60 | 40 | YES | 5 | 40 | Intermediate | Our study |
| 580    | MTRR2    | NM_0016156.5 | c.[460T > C] | rs57651426 | Heterozygous | 601382 | 4 | SCVO01142425 | PM2-PM4-PP3-PP4 | 30 | 22 | YES | 2 | >35 | Intermediate | Our study |
| 184    | KIF1A    | NM_00124400.8 | c.[5232C > T] | rs66968490 | Heterozygous | 614213 | 4 | SCVO01132011.2 | PM2-PP2-PP3-PP4 | 67 | 45 | NO | 5 | 25 | Slow | Our study |
| 721    | AGRN     | NM_198576.4 | c.[5851C > T] | rs461179370 | Heterozygous | 615120 | 3 | SCVO011377285 | PM2-PP3-PP1 | 59 | 55 | NO | 2 | >15 | Very slow | Our study |
| 721    | SCP2     | NM_002979.5 | c.[886C > T] | rs613724 | Heterozygous | 613724 | 3 | SCVO01142425 | PM2-PP3 | 59 | 55 | NO | 2 | 15 | Slow | Our study |
| 856    | DNM2     | NM_001003690.2 | c.[800G > A] | rs689436464 | Heterozygous | 6482 | 3 | SCVO00762731.1 | PM2-PP2-PP3 | 67 | NA | NO | 1 | >35 | Slow | Our study |
| 608    | MEDE25   | NM_0013973.3 | c.[949G > T] | rs1122352 | Heterozygous | 605989 | 3 | SCVO01142425 | PM2-PP3-PP1 | 53 | 50 | NO | 2 | >35 | Intermediate | Our study |
| 962    | DWNC1H1  | NM_001376.4 | c.[8603T > G] | rs607831 | Heterozygous | 614228 | 3 | SCVO01142425 | PM1-PM2-PP4 | 36 | 34 | NO | 1 | 20 | Slow | Our study |
| 731    | DWNC1H1  | NM_001376.4 | c.[8643A > G] | rs607831 | Heterozygous | 614228 | 3 | SCVO01142425 | PM2-PP3 | 63 | NA | 1 | <35 | Slow | Our study |

**FAM ID, Family identification; HGVSc, Nomenclature human genome variation society coding DNA; HGVSp, Nomenclature human genome variation society protein; dbsNP ID, Single nucleotide polymorphism database; ACMG, American college of medical genetics guideline; AY, Years at evaluation; AO, Age at onset; CMT subtype, Demyelinating CMT=1, Axonal CMT =2, dHMN=3, HSN=4, and Possible CMT=5; CV, Conduction velocity m/s; CV subtype, CMT subtype classification for conduction velocity; PVS1, Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multixletion deletion) in a gene where LOF is a known mechanism of disease (pathogenic and very strong); PM1, Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation (pathogenic and moderate); PM2, Ablent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium (pathogenic and moderate); PM3, Frequent variants in a gene with a known disease (pathogenic and moderate); PM4, Protein length changes as a result of in-frame deletions/insertions in a non-repeat region or stop-loss variants (pathogenic and moderate); PP1, Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease (pathogenic and supporting); PP2, Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease (pathogenic and supporting); PP3, Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.; pathogenic and supporting); PP4, Patient's phenotype or family history is highly specific for a disease with a single genetic etiology (pathogenic and supporting); BP1, Missense variant in a gene for which primarily truncating variants are known to cause disease (benign and supporting); BP4, Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.; benign and supporting).**
pathogenic because of its presence in homozygous in her affected brother (II:2), and in heterozygous in her parents (I:1 and I:2). Thus, this variant is responsible for CMT disease, type 4B1, and autosomal recessive (MIM 601382).

**Variants Identified as VoUs**
Seven VoUS were found in 6/67 patients (7%; Table 2; Figure 2A). Heterozygous variants identified in AGRN, SCP2, DNM2, MED25, DYN1H1, and BSCL2 genes associated with autosomal dominant and recessive CMT.

**Family ID 721**
The proband, a 59 years old male (II:1; Figure 3A), onset at 55 years old, presented with axonal neuropathy. He showed a very slow conduction velocity (>15 m/s). He had clear psychic slowness, cognitive impairment, and floating paresthesia in the upper limbs. Molecular analysis identified two new heterozygous missense mutations: (a) in AGRN (MIM 103320) NM_198576.4:c.[5851C > T], NP_940978.2: p.(Arg1951Cys), (rs746117937) responsible for myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, autosomal recessive (MIM 615120), and SCP2 (MIM 184755) NM_002979.5:c.[886C > T] and NP_001317516.1:p. (Pro296Ser) responsible for leukoencephalopathy with dystonia and motor neuropathy, autosomal recessive (MIM 613724). Both variants are not present in the healthy sister (II:2), but these data are not sufficient to consider this variant as likely pathogenic.

**Family ID 856**
The proband, a 67 years old female (II:1; Figure 3B), presented with axonal neuropathy. She showed a slow conduction velocity (<35 m/s). Molecular analysis identified a new heterozygous missense mutation: NM_010005360.2:c.[890G > A], NP_001005360.1:p.(Arg297His; rs763894364) in DNM2 (MIM 602378) responsible for CMT disease, axonal type 2M, and autosomal dominant (MIM 606482). Family members were not available for testing.

**Family ID 608**
The proband, a 53 years old female (II:1; Figure 3C), onset at 50, presented with axonal neuropathy. She showed an intermediate conduction velocity (<35 m/s). Molecular analysis identified a new heterozygous missense mutation: NM_030973.3:c.[949G > T], NP_112235.2:p.(Gly317Cys; rs1280659782 G > T) in MED25 (MIM 610197) responsible for CMT disease, type 2B, and autosomal recessive (MIM 605589). Family members were not available for testing.

**Family ID 962**
The proband, 36 years old male (II:1; Figure 3D), onset at 34, presented with demyelinating neuropathy. He showed a slow conduction velocity (20 m/s). Molecular analysis identified a new heterozygous missense mutation: NM_001376.4:c.[9919G > T], NP_001367.2:p.(Val3307Leu) in DYN1H1 (MIM 600112) responsible for CMT disease, type 20, and autosomal dominant (MIM 614228). Family members were not available for testing.

**Family ID 731**
The proband, 63 years old female (II:1; Figure 3E), presented with axonal neuropathy. She showed a slow conduction velocity (<35 m/s). Molecular analysis identified a new heterozygous missense mutation: NM_001376.4:c.[6743A > G], NP_001367.2:p. (Glu2248Gly) in DYN1H1 (MIM 600112) responsible for CMT disease, type 20, and autosomal dominant (MIM 614228). Family members were not available for testing.

**Family ID 1261**
The proband, 48 years old male (II:1; Figure 3F), onset at 42 years old, presented with demyelinating neuropathy. He showed a very slow conduction velocity (>15 m/s) and hollow foot. Molecular analysis identified a new heterozygous missense mutation: NM_001122955.3:c.[124C > T], NP_001116427.1:p.(Arg42Cys); (rs201493733) in BSCL2 (MIM 606158), responsible for neuropathy, distal hereditary motor, and type VA (MIM 600794) autosomal dominant. Family members were not available for testing.

**DISCUSSION**
In this study, 67 patients with a clinical diagnosis of CMT were selected for molecular analysis of genes known to be related to the disease. Although the genetic of CMT is featured by a strong genetic heterogeneity, most of the patients carry 17p CNV of PMP22. Among this CNV, almost all cases carry the whole gene duplication of PMP22. The prevalence of the duplication varies among populations, ranging from 15% in Norwegian studies, up to more than 50% in Italy and Spain (Abe et al., 2011; Saporta et al., 2011; Murphy et al., 2012; Østern et al., 2013; Sivera et al., 2013; Hoyer et al., 2014). In this study, only 30% of Italian patients (20/67) carry the whole gene duplication of PMP22, thus under-representing other Italian studies though still being in line with prevalence measured in European studies (Figure 2B).

When ruling out carriers of 17p CNV in PMP22, NGS identified the causative variants in 8/41 patients, which correspond only to 12% of the patients analyzed in this study (8 out of 67), being over 50% of the total of causative variants confirming the clinical diagnosis detected in the present analysis. Thus, combining various genetic tools using a target panel of 49 genes allowed to cover to a greater extent the complex clinical setting.

Several cohort studies tried to identify the diagnostic yield in CMT patients. To this aim, we conducted a systematic review of 23 cohort analysis studies consisting of Italian and European CMT patients in the period between 1997 and 2020. This data, summarized in Figure 2B and Supplementary data, identified a diagnostic yield of 71.7% in Italy (Mostacciolo et al., 2001; Manganelli et al., 2014; Gentile et al., 2020) and 26.7% in Europe (Bort et al., 1997; Saporta et al., 2011; Murphy et al., 2012; Gess et al., 2013; Østern et al., 2013; Sivera et al., 2013; Hoyer et al., 2014; Antoniadi et al., 2015; LaŠšuhová et al., 2016; Lupo et al., 2016; Dohrn et al., 2017; Martínl et al., 2017; Bacquet et al., 2018; Hoebeke et al., 2018; Milley et al., 2018; Nicolas et al., 2018; Lerat et al., 2019; Vaeth et al., 2019;
Cortese et al., 2020; Figure 2B). Therefore, the prevalence of genetic cases of CMT provided by the present data represents an average compared with the general prevalence measured in Italy and Europe. The differences in the diagnostic rate may be explained by the differences in the specific features of the cohorts being analyzed, the number of demyelinating CMT cases enrolled, and the heterogeneous inclusion criteria considering the common causative, which were genes adopted by the previous MLPA and Sanger sequencing.

In our cohort, NGS approach identified variants in eight different genes: \(\text{MFN2, MPZ, GDAP1, SH3TC2, HSPB1, KIF5A, MTMR2, and KIF1A (Table 2)}\), five responsible for demyelinating CMT, and three for axonal or intermediate CMT. These NGS-identified variants appeared as sporadic (3/8) or familial (5/8).
A frequency of sporadic or *de novo* mutations is reported in 28–34% (Marques et al., 2005; Ando et al., 2017), although this percentage may vary and some studies report up to a half of the patients as sporadic (Ando et al., 2017). In this study, variants considered as sporadic are reported in three out of eight patients with a NGS genetic diagnosis (37.5%). This percentage, in line with other studies, may represent an overestimation since this trend cannot be verified in a few families where a full familial anamnesis is lacking. This point is crucial since it demonstrates how a careful, multifaceted genetic approach with a complete familial anamnesis and genetic segregation analysis could provide a reduction of sporadic CMT.

Among sporadic variants, the proband Family ID 564 (Figure 1A) is a carrier of a whole gene mosaic in the PMP22 gene. This is consistent with the high instability of the PMP22 gene which undergoes *de novo* PMP22 duplications in up to 90% of sporadic CMT1 (Boerkoel et al., 2002; Marques et al., 2005).

The other probands carry sporadic variants in the gene MFN2, MPZ, and HSPB1. Mutations in MFN2 cause CMT type 2A by altering mitochondrial fusion and trafficking along with the axonal microtubule system (Guerriero et al., 2020). Pathogenic variants in MFN2 are typically inherited as autosomal dominant and are usually nonsense variants (Di Vincenzo et al., 2014).

The sporadic variant identified, Family ID 883 (Figure 1B), consists of a single base insertion in the coiled-coil domains producing a stop mutation p.(Gln754AlafsTer9). This could be a *de novo* variant. *De novo* MFN2 mutations are regularly found in patients with a classical CMT2 phenotype (Östern et al., 2013), and some MFN2 mutations have also been reported as *de novo* in several patients (Züchner et al., 2004; Chung et al., 2006; Verhoeven et al., 2006; Cho et al., 2007). The early onset of the proband, at 7 years old, is in line with data reporting that mutations in MPZ, MFN2, or NEFL are the most frequent disease causes of patients with infantile-onset CMT (Hsu et al., 2019).

Thanks to NGS studies, several data are broadening the phenotype spectrum produced by mutations in some CMT genes. For example, mutations in the N-terminal motor domain of KIF5A are responsible for hereditary spastic paraplegia (SPG10 MIM 604187) and CMT type 2 (CMT2), clustered in the switch regions SW1 (199–204) and SW2 (232–237) necessary for microtubules interaction (Filosto et al., 2018). On the other hand, mutations in the C-terminal cargo-binding tail domain (Tail domain) are related to a specific ALS phenotype (ASL MIM 617921), with an early disease onset but a longer survival compared with typical amyotrophic lateral sclerosis (ALS; Brenner et al., 2018; Nicolas et al., 2018). Beyond these main phenotypes, other complex and overlapping phenotypes are emerging, which demonstrates that KIF5A mutations may be responsible for a wide range and heterogeneous disease spectrum (Schüle et al., 2008; Tessa et al., 2008). For example, in a patient, a mixed slowly progressive disease was described resembling ALS as well as HSP and axonal neuropathy. This is caused by a mutation within the terminal region of the stalk domain (Cho et al., 2007). Additionally, the patient Family ID 1141 (Figure 1H) reported in this paper represents the first case of a familial mutation, the new heterozygous deletion p.Leu957del, falling in the tail domain of KIF5A producing spastic paraplegia 10 with autosomal dominant neuropathy (MIM 604187).

Taken together, these results broaden the phenotypic spectrum of KIF5A mutations and confirm the importance of cytoskeletal defects in the pathogenesis of both ALS and CMT.

In line with this, the phenotype related to heat shock protein 27 (HSP27) is broadening. For instance, mutations in the HSPB1 gene have been reported to cause autosomal dominant CMT with minimal sensory involvement (CMT 2F MIM 606595). Then, two independent studies reported different HSPB1 mutations in two sporadic cases and one consanguineous family with ALS, suggesting that the disease spectrum of HSP27 may not be limited to CMT2/dHMN (Scarlato et al., 2015; Capponi et al., 2016; Adriaenssens et al., 2017). In this study, we identified the known heterozygous missense mutation p.Gln190H in Family ID 402 (Figure 1D), which falls in the C-terminal domain involved in the control of its chaperone-like activity, responsible for CMT, axonal, and type 2F autosomal dominant (MIM 606595; Lelj-Garolla and Mauk, 2012). This variant falls in the C-terminal domain involved in the control of chaperone-like activity (Lelj-Garolla and Mauk, 2012; Capponi et al., 2016). It has been previously reported in a sporadic ALS patient with onset at 58 yo, and axonal neuropathy with an intermediate conduction velocity (38 m/s; Capponi et al., 2016). Therefore, considering this study in which the same variant has been identified in a CMT patient, the genotype-phenotype correlation is very complex. Functional characterization of different mutations located in the C-terminal domain did not show a clear correlation between the location of the mutation and associated cellular phenotype. This suggested that the genomic variant, more than its location, determines the cell pathology and phenotype. However, the present study contradicts such a conclusion which is not consistent with the present data which indicate how the same substitution has been identified in patients owing to a different disease (ALS in one case CMT in another; Capponi et al., 2016). This suggests the importance of how specific genetic backgrounds may alter the expression of the genetic variants while explaining how rare variants, like VoUS may be responsible for the disease.

In this study, seven VoUS were identified in six (7%) patients. These variants, all in heterozygous status, all fall in one of those genes associated with autosomal dominant and recessive CMT: AGRN, SCP2, DNMT2, MED25, DYN1H1, and BSCL2. This high number of VoUS is in line with the previous studies reporting a higher number of VoUS in neuropathy-associated genes, including single mutations in autosomal recessive CMT genes compared with the control population, with some patients presenting more than one VoUS in different CMT genes (Gonzaga-Jauregui et al., 2015). For instance, here, we report multiple VoUS in the proband of Family ID 721 (Figure 3A) characterized by two VoUS in AGRN and SCP2. A recent hypothesis suggests that a combinatorial effect of rare variants contributes to the disease burden in CMT and partly explains its various phenotypes. This confirms what was demonstrated by using *in vivo*...
experimental models in zebrafish (Cortese et al., 2020). Therefore, the interpretation of VoUS remains a key diagnostic challenge in the current NGS era.

**CONCLUSION**

This cohort analysis demonstrates the importance of combining different molecular approaches to identify the causative variant in CMT patients. The use of NGS target panel consisting of 49 genes identified the causative variants in eight patients, improving the detection rate to 50.8%. Although this seems to represent only a small fraction of patients, the identification of rare mutations allows dissecting of unexpected phenotypes associated with previously known or unknown genotypes, thus broadening the phenotype expression produced by variants. This is the example of a patient carrying a novel familial mutation in the tail domain of KIF5A (a protein domain previously associated with familial ALS), and a CMT patient carrying an HSPB1 mutation, previously reported in ALS.

In this cohort, the higher frequency of VoUS identified is in line with the previous studies, confirming that the interpretation of VoUS remains a key diagnostic challenge in the current NGS era. In line with this, in this cohort, the segregation analysis allowed to correctly interpret two variants, initially reported as VoUS, but re-classified as pathological.

To improve the detection rate in CMT patients, whole-genome sequencing (WGS) and whole-exome sequencing (WES) are strongly required. While the use of WES is now accepted for diagnostic purposes, WGS is able to both identify novel and rare variants in coding as well as noncoding regions. Therefore, these approaches allow the identification of new genes and rare variants, thus improving the genetic detection rate.

**DATA AVAILABILITY STATEMENT**

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

**REFERENCES**

Abe, A., Numakura, C., Kijima, K., Hayashi, M., Hashimoto, T., and Hayasaka, K. (2011). Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. J. Hum. Genet. 56, 364–368. doi: 10.1038/jhg.2011.20

Adriaenssens, E., Geuens, T., Baets, J., Echaniz-Laguna, A., and Timmerman, V. (2017). Novel insights in the disease biology of mutant small heat shock proteins in neuromuscular diseases. Brain 140, 2541–2549. doi: 10.1093/brain/awx187

Ando, M., Hashiguchi, A., Okamoto, Y., Yoshimura, A., Hiramatsu, Y., Yuan, J., et al. (2017). Clinical and genetic diversities of Charcot-Marie-Tooth disease with MFN2 mutations in a large case study. J. Peripher. Nerv. Syst. 22, 191–199. doi: 10.1111/jnns.12228

Antoniadi, T., Buxton, C., Dennis, G., Forrester, N., Smith, D., Lunt, P., et al. (2015). Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield with unexpected phenotype-genotype variability. BMC Med. Genet. 16:84. doi: 10.1186/s12881-015-0224-8

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by IRCCS Neuromed Ethical Committees. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

CD, FB, DC, GL, CZ, SZ, AS, FF, VC, EM, EG, MM, and LS performed the recruitment and clinical evaluations of patients. RF, RC, and SS performed the genetic analyses. DC, FF, GN, MS, and SG supervised the work. RF and SG wrote the first draft of the manuscript. All authors read the manuscript, contributed to the manuscript revision, and approved the final version.

**FUNDING**

This work was supported by the Italian Ministry of Health (current research 2019–2023: Identification of New Variants and/or New Genes Responsible for Ataxia and Spastic Paraplegia), (5XMille – 2018).

**ACKNOWLEDGMENTS**

The authors are grateful to the patients and their relatives participating in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fgene.2021.682050/full#supplementary-material
Ferre et al. | Analysis of 67 Charcot-Marie-Tooth Italian Patients

Bort, S., Nels, E., Timmerman, V., Sevilla, T., Cruz-Martínez, A., Martínez, F., et al. (1997). Mutation analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. *Hum. Genet.* 99, 746–754. doi: 10.1007/s004390050442

Braithen, G. J., Sand, J. C., Lobato, A., Hoyer, H., and Russell, M. B. (2011). Genetic epidemiology of Charcot-Marie-Tooth in the general population. *Eur. J. Neurol.* 18, 39–48. doi: 10.1111/j.1468-1331.2010.03037.x

Brenner, D., Yilmaz, R., Müller, K., Grehl, T., Petri, S., Meyer, T., et al. (2018). Hot-spot KIF5A mutations cause familial ALS. *Brain* 141, 688–697. doi: 10.1093/brainawx70

Capponi, S., Geuens, T., Geroldi, A., Origone, P., Verdiani, S., Cichero, E., et al. (2016). Molecular chaperones in the pathogenesis of amyotrophic lateral sclerosis: the role of HSPB1. *Hum. Mutat.* 37, 1202–1208. doi: 10.1002/humu.23062

Cho, H. J., Sung, D. H., Kim, B. J., and Ki, C. S. (2007). Mitochondrial GTPase mitofusin 2 mutations in Korean patients with Charcot-Marie-Tooth neuropathy type 2. *Clin. Genet.* 71, 267–272. doi: 10.1111/j.1399-0004.2007.00763.x

Chung, K. W., Kim, S. B., Park, K. D., Choi, K. G., and Lee, J. H. (2006). Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. *Brain* 129, 2103–2118. doi: 10.1093/brain/awl174

Cortese, A., Wilcox, J. E., Polke, J. M., Poh, R., and Skorupsinska, M. (2020). Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. *Neuropathy* 94, e51–e61. doi: 10.1212/WNL.0000000000008672

Di Vincenzo, C., Elzinga, C. D., Medeiros, A. C., Karbassi, I., and Jones, J. R. (2014). The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. *Hum. Genet. Genomic. Med.* 2, 522–529. doi: 10.1002/mgm.3106

Doehm, M. E., Glöckle, N., Mulhasanovic, L., Heller, C., Mohr, J., Bauer, C., et al. (2017). Frequent genes in rare diseases: panel-based next generation sequencing to disclose causal mutations in hereditary neuropathies. *J. Neurochem.* 143, 507–522. doi: 10.1111/jnc.14217

Filosto, M., Piccinelli, S. C., Palmieri, I., Necchini, N., and Valente, M. (2018). A novel mutation in the stalk domain of KIF5A causes a slowly progressive atypical motor syndrome. *J. Clin. Med.* 8:17. doi: 10.3390/jcm8010017

Gentile, L., Russo, M., Fabrizi, G. M., Taioli, F., Ferrari, M., Testi, S., et al. (2020). Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. *Neurosci. Lett.* 641, 1239–1243. doi: 10.1016/j.selneuro.2019.04.2219-1

Gess, B., Schirmacher, A., Boentert, M., and Young, P. (2013). Charcot-Marie-Tooth disease: frequency of genetic subtypes in a Southern Italy population. *J. Peripher. Nerv. Syst.* 19, 292–298. doi: 10.1111/jnns.12092

Marques, W. J., Freitas, M. R., Oliveira, A. S. B., Calia, L., Melo, A., Lucena, R., et al. (2005). 17p duplicated Charcot–Marie–Tooth 1A: characteristics of a new population. *J. Neurol.* 252, 972–979. doi: 10.1007/s00410-005-0797-9

Manganelli, F., Tozza, S., Piscicotta, C., Bellone, E., Iodice, R., Nolano, M., et al. (2014). Charcot-Marie-Tooth disease: frequency of genetic subtypes in a Southern Italy population. *J. Peripher. Nerv. Syst.* 19, 292–298. doi: 10.1111/jnns.12092

Milley, G. M., Varga, E. T., Grosz, Z., Nemes, C., Arányi, Z., Boczán, J., et al. (2018). Genotypic and phenotypic spectrum of the most common causative genes of Charcot-Marie-Tooth disease in Hungarian patients. *Neuromuscul. Disord.* 28, 38–43. doi: 10.1016/j.nmd.2017.08.007

Mostacciolo, M. L., Righetti, E., Zorretta, M., Bosello, V., and Schiavon, F. (2001). Charcot-Marie-Tooth disease type I and related demyelinating neuropathies: mutation analysis in a large cohort of Italian families. *Hum. Mutat.* 18, 32–41. doi: 10.1002/humu.1147

Murphy, S. M., Laura, M., Fawcett, K., Pandraud, A., Liu, Y. T., Davidson, G. L., et al. (2012). Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. *J. Neurol. Neurosurg. Psychiatry* 83, 706–710. doi: 10.1136/jnnp-2012-302451

Nicolas, A., Kenna, K. P., Benton, A. E., Ticozzi, N., Faghri, F., Chia, R., et al. (2013). Genome-wide analyses identify KIF5A as a novel ALS gene. *Neuron* 97, 1268–1283. doi: 10.1162/ajnaj.2018.02.027

OMIM (2014). Online Mendelian Inheritance in Man, OMIM (TM). Available at: http://www.ncbi.nlm.nih.gov/omim/

Ostern, R., Fagerheim, T., Hjelnes, H., Nygård, B., Mellgren, S. I., and Nilssen, Ø. (2013). Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies. *BMC Med. Genet.* 14:94. doi: 10.1186/1471-2350-14-94

Piscosquito, G., Saveri, P., and Magri, S. (2016). Screening for SH3T2C gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). *J. Peripher. Nerv. Syst.* 21, 142–149. doi: 10.1111/jns12175

Rautenstrauss, B., Liehr, T., Fuchs, C., Bevot, A., Bornemann, A., Postler, E., et al. (1998). Mosaicism for Charcot-Marie-Tooth disease type I: onset in childhood suggests somatic reversion in early developmental stages. *Int. J. Mol. Med.* 1, 333–337. doi: 10.3892/immm.1.2.333

Reilly, K. M., and Shi, M. E. (2009). Diagnosis and new treatments in genetic neuropathies. *J. Neurol. Neurosurg. Psychiatry* 80, 1304–1314. doi: 10.1136/jnnp.2008.158295

Rossov, A. M., Polke, J. M., Houlden, H., and Reilly, M. M. (2013). Clinical implications of genetic advances in Charcot-Marie-Tooth disease. *Nat. Rev. Neurol.* 9, 562–571. doi: 10.1038/nrneurol.2013.179

Saifi, G. M., Szigeti, K., Snipes, G. J., Garcia, C. A., and Lupski, J. R. (2003). Roles of the N- and C-terminal sequences in Hsp27 self-association and chaperone activity. *Protein Sci.* 12, 125–134. doi: 10.1111/j.1365-2958.2002.tb03077.x

Safizadeh, A., Shires, J. M., and Gilsbach, J. A. (2013). Assessment of targeted next-generation sequencing as a tool for the diagnosis of Charcot-Marie-Tooth disease and hereditary motor neuropathy. *J. Mol. Diagn.* 15, 225–234. doi: 10.1016/j.jmoldx.2015.10.005
## GLOSSARY

| Abbreviation | Description |
|--------------|-------------|
| FAM ID       | Family identification |
| HGVS c       | Nomenclature human genome variation society coding DNA |
| HGVS p       | Nomenclature human genome variation society protein |
| dbSNP ID     | Single-nucleotide polymorphism database |
| ACMG         | American College of Medical Genetics Guideline |
| AY           | Years at evaluation |
| AO           | Age at onset |
| CMT subtype  | Demyelinating CMT = 1, axonal CMT = 2, dHMN = 3, HSN = 4, and possible CMT = 5 |
| CV           | Conduction velocity m/s |
| CV subtype   | CMT subtype classification for conduction velocity |
| PVS1         | Null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, termination codon, single, or multiexon deletion) in a gene where LOF is a known mechanism of disease (pathogenic and very strong) |
| PM1          | Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation (pathogenic and moderate) |
| PM2          | Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1,000 Genomes Project, or Exome Aggregation Consortium (pathogenic and moderate) |
| PM3          | For recessive disorders, detected in trans with a pathogenic variant (pathogenic and moderate) |
| PM4          | Protein length change as a result of in-frame deletions/insertions in a nonrepetitive region or stop-loss variants (pathogenic and moderate) |
| PP1          | Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (pathogenic and supporting) |
| PP2          | Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease (pathogenic and supporting) |
| PP3          | Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.; pathogenic and supporting) |
| PP4          | Patient's phenotype or family history is highly specific for a disease with a single genetic etiology (pathogenic and supporting) |
| BP1          | Missense variant in a gene for which primarily truncating variants is known to cause disease (benign and supporting) |
| BP4          | Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.; benign and supporting). |